Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Non-cash Items (2016 - 2025)

Historic Non-cash Items for Adma Biologics (ADMA) over the last 11 years, with Q3 2025 value amounting to $2.8 million.

  • Adma Biologics' Non-cash Items rose 990.54% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year increase of 990.54%. This contributed to the annual value of $68.1 million for FY2024, which is 66415.75% up from last year.
  • Adma Biologics' Non-cash Items amounted to $2.8 million in Q3 2025, which was up 990.54% from $11.1 million recorded in Q2 2025.
  • Adma Biologics' 5-year Non-cash Items high stood at $68.1 million for Q4 2024, and its period low was $35935.0 during Q4 2021.
  • Its 5-year average for Non-cash Items is $8.7 million, with a median of $5.6 million in 2022.
  • Per our database at Business Quant, Adma Biologics' Non-cash Items soared by 2116128.29% in 2022 and then crashed by 5526.54% in 2025.
  • Over the past 5 years, Adma Biologics' Non-cash Items (Quarter) stood at $35935.0 in 2021, then soared by 21161.28% to $7.6 million in 2022, then grew by 16.67% to $8.9 million in 2023, then surged by 664.16% to $68.1 million in 2024, then plummeted by 95.95% to $2.8 million in 2025.
  • Its last three reported values are $2.8 million in Q3 2025, $11.1 million for Q2 2025, and $3.1 million during Q1 2025.